Neurofibroma, Plexiform
Showing 1 - 25 of 89
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group
Not yet recruiting
- Neurofibromatosis 1
- +2 more
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Control group (Group B): Placebo, orally, once daily;
- (no location specified)
Jun 16, 2023
Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma Plexiform
-
Shanghai, China
- +1 more
Jan 13, 2023
Disfigurement From Photographs of Neurofibromatosis Type 1
Completed
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))
Active, not recruiting
- Neurofibromatosis 1
- Neurofibroma, Plexiform
- Medication Event Monitoring System (MEMS)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
(PRO) Measures for Individuals With Neurofibromatosis 1 and
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)
Active, not recruiting
- Neurofibromatosis 1
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)
Active, not recruiting
- Neurofibromatosis 1 (NF1)
- Plexiform Neurofibromas (PN)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Neurofibroma, Neurofibroma, Plexiform Trial (Cryotherapy)
Not yet recruiting
- Neurofibroma
- Neurofibroma, Plexiform
- Cryotherapy
- (no location specified)
Jan 19, 2022
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Neurofibromatosis, MPNST Trial run by the National Cancer Institute (NCI) (MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans)
Completed
- Neurofibromatosis
- MPNST
- MRI, FDG-PET/CT scans
- [18F]-FLT-PET/CT scans
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Low-grade Glioma, Plexiform Neurofibroma, CNS Glioma Trial in Canada (Trametinib)
Active, not recruiting
- Low-grade Glioma
- +2 more
-
Calgary, Alberta, Canada
- +6 more
Oct 25, 2022
Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
-
Shanghai, Shanghai, ChinaShanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022
Malignant Peripheral Nerve Sheath Tumor Development in
Active, not recruiting
- Neurofibromatosis 1
- Peripheral Nerve Neoplasms, Malignant
-
Bethesda, MarylandNational Cancer Institute (NCI)
Jul 6, 2022
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
-
Rochester, Minnesota
- +8 more
Nov 10, 2022
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Tumor, Other MAP-K Pathway Driven Diseases Trial
Available
- Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
- +2 more
- Mirdametinib (MEK Inhibitor)
- (no location specified)
Aug 24, 2021
Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibroma (PN)
- Selumetinib
- Placebo
-
Gainesville, Florida
- +40 more
Jan 16, 2023
PET/MRI in CNS and Extra-CNS Tumors of Neurofibromatosis-1 (NF1)
Completed
- Neurofibromatosis-1
- +2 more
-
Chapel Hill, North CarolinaUniversity of North Carolina-Chapel Hill
May 11, 2021
Neurofibroma, Plexiform Trial in Indianapolis (Imatinib Mesylate)
Withdrawn
- Neurofibroma, Plexiform
- Imatinib Mesylate
-
Indianapolis, IndianaRiley Hospital for Children - Indiana University
Feb 9, 2021
Neurofibromatosis 1, NF1, Neurofibromatosis Type 1 Trial in Chicago
Recruiting
- Neurofibromatosis 1
- +2 more
-
Chicago, IllinoisAnn & Robert H. Lurie Children's Hospital of Chicago
Mar 11, 2022
Neurofibromatosis 1, Neurofibroma, Atypical Neurofibroma Trial in Washington (Whole Body MRI)
Active, not recruiting
- Neurofibromatosis 1
- +5 more
- Whole Body MRI
-
Washington, District of ColumbiaChildren's National Health System
Feb 26, 2021